MolNFT v2 · #225437 · protein
Rhodothermus marinus alpha-amylase RmGH13_47A CBM48-A-B-C domains
8XX9: “Rhodothermus marinus alpha-amylase RmGH13_47A CBM48-A-B-C domains”. X-ray diffraction at 1.55, 2 ligands (MN, CA), 4 pockets (best druggability 0.65). MolNFT v2 #225437 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 8XX9
- Type
- protein
- Length
- 620 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v2 / PDB Bank
- Contract
- 0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
- Owner
- 0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
- Resolution
- 1.55
- Source
- Rhodothermus marinus JCM 9785
- Molecule
- alpha-amylase
- EC
- 3.2.1.1
- Ligands
- MN, CA
- Pockets
- 4 · best druggability 0.65
Structure
x-ray diffraction · resolution 1.55 · 1 distinct chain · 27% helix, 23% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | alpha-amylase (EC 3.2.1.1) | protein | 620 | 27% helix, 23% strand | — |
Ligands and binding sites
- MN · Manganese (II) ion · metal · chains A
- CA · Calcium ion · metal · chains A
- MES · 2-(N-morpholino)-ethanesulfonic acid · additive · 2 copies · chains A
- MPD · (4S)-2-methyl-2,4-pentanediol · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 377 | 0.65 | 0.79 | 41 | empty |
| 2 | 254 | 0.50 | 0.74 | 27 | empty |
| 3 | 85 | 0.41 | 0.78 | 17 | empty |
| 4 | 106 | 0.36 | 0.74 | 19 | empty |
Modifications
Observed in the structure: 1 disulfide (disulfide).
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Elsewhere: RCSB PDB 8XX9 · PDBe 8XX9
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.